Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in Humans
Identifieur interne : 001574 ( Pmc/Curation ); précédent : 001573; suivant : 001575Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in Humans
Auteurs : Ming Qiao ; David Shaw ; Remi Forrat ; Anh Wartel-Tram ; Jean LangSource :
- The American Journal of Tropical Medicine and Hygiene [ 0002-9637 ] ; 2011.
Abstract
A dengue vaccine effective against all four serotypes is urgently needed. However, safety and immunogenicity could be affected by prior exposure to flaviviruses. This open, controlled, phase IIa study was conducted in 35 healthy adults who had received monovalent, live attenuated Vero cell-derived dengue vaccine against dengue virus 1 (VDV1) or 2 (VDV2) or yellow fever (YF) vaccine 1 year before or who were flavivirus-naïve. All participants received one subcutaneous injection of tetravalent dengue vaccine (TDV) and were followed for 180 days. Previous vaccination did not increase reactogenicity, laboratory abnormalities, or incidence of vaccine viremia, but it did increase the neutralizing antibody response to dengue virus that persisted at day 180. There was no increase in YF antibodies in participants previously immunized with YF vaccine. Prior exposure to YF or monovalent dengue vaccines had no adverse effects on the safety or incidence of viremia associated with this TDV, but it increased immunogenicity.
Url:
DOI: 10.4269/ajtmh.2011.10-0436
PubMed: 21976579
PubMed Central: 3183784
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001714
Links to Exploration step
PMC:3183784Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in Humans</title><author><name sortKey="Qiao, Ming" sort="Qiao, Ming" uniqKey="Qiao M" first="Ming" last="Qiao">Ming Qiao</name></author><author><name sortKey="Shaw, David" sort="Shaw, David" uniqKey="Shaw D" first="David" last="Shaw">David Shaw</name></author><author><name sortKey="Forrat, Remi" sort="Forrat, Remi" uniqKey="Forrat R" first="Remi" last="Forrat">Remi Forrat</name></author><author><name sortKey="Wartel Tram, Anh" sort="Wartel Tram, Anh" uniqKey="Wartel Tram A" first="Anh" last="Wartel-Tram">Anh Wartel-Tram</name></author><author><name sortKey="Lang, Jean" sort="Lang, Jean" uniqKey="Lang J" first="Jean" last="Lang">Jean Lang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">21976579</idno><idno type="pmc">3183784</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3183784</idno><idno type="RBID">PMC:3183784</idno><idno type="doi">10.4269/ajtmh.2011.10-0436</idno><date when="2011">2011</date><idno type="wicri:Area/Pmc/Corpus">001714</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001714</idno><idno type="wicri:Area/Pmc/Curation">001574</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001574</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in Humans</title><author><name sortKey="Qiao, Ming" sort="Qiao, Ming" uniqKey="Qiao M" first="Ming" last="Qiao">Ming Qiao</name></author><author><name sortKey="Shaw, David" sort="Shaw, David" uniqKey="Shaw D" first="David" last="Shaw">David Shaw</name></author><author><name sortKey="Forrat, Remi" sort="Forrat, Remi" uniqKey="Forrat R" first="Remi" last="Forrat">Remi Forrat</name></author><author><name sortKey="Wartel Tram, Anh" sort="Wartel Tram, Anh" uniqKey="Wartel Tram A" first="Anh" last="Wartel-Tram">Anh Wartel-Tram</name></author><author><name sortKey="Lang, Jean" sort="Lang, Jean" uniqKey="Lang J" first="Jean" last="Lang">Jean Lang</name></author></analytic><series><title level="j">The American Journal of Tropical Medicine and Hygiene</title><idno type="ISSN">0002-9637</idno><idno type="eISSN">1476-1645</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>A dengue vaccine effective against all four serotypes is urgently needed. However, safety and immunogenicity could be affected by prior exposure to flaviviruses. This open, controlled, phase IIa study was conducted in 35 healthy adults who had received monovalent, live attenuated Vero cell-derived dengue vaccine against dengue virus 1 (VDV1) or 2 (VDV2) or yellow fever (YF) vaccine 1 year before or who were flavivirus-naïve. All participants received one subcutaneous injection of tetravalent dengue vaccine (TDV) and were followed for 180 days. Previous vaccination did not increase reactogenicity, laboratory abnormalities, or incidence of vaccine viremia, but it did increase the neutralizing antibody response to dengue virus that persisted at day 180. There was no increase in YF antibodies in participants previously immunized with YF vaccine. Prior exposure to YF or monovalent dengue vaccines had no adverse effects on the safety or incidence of viremia associated with this TDV, but it increased immunogenicity.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Trop Med Hyg</journal-id><journal-id journal-id-type="publisher-id">tpmd</journal-id><journal-title-group><journal-title>The American Journal of Tropical Medicine and Hygiene</journal-title></journal-title-group><issn pub-type="ppub">0002-9637</issn><issn pub-type="epub">1476-1645</issn><publisher><publisher-name>The American Society of Tropical Medicine and Hygiene</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21976579</article-id><article-id pub-id-type="pmc">3183784</article-id><article-id pub-id-type="doi">10.4269/ajtmh.2011.10-0436</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in Humans</article-title><alt-title alt-title-type="left-running-head">QIAO AND OTHERS</alt-title><alt-title alt-title-type="right-running-head">FLAVIVIRUS IMMUNITY AND DENGUE VACCINE IMMUNOGENICITY</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Qiao</surname><given-names>Ming</given-names></name><xref ref-type="corresp" rid="COR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Shaw</surname><given-names>David</given-names></name></contrib><contrib contrib-type="author"><name><surname>Forrat</surname><given-names>Remi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wartel-Tram</surname><given-names>Anh</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lang</surname><given-names>Jean</given-names></name></contrib></contrib-group><aff id="AFF1">Microbiology and Infectious Diseases, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia; Infectious Diseases Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia; Sanofi Pasteur, Lyon, France; Sanofi Pasteur, Thailand</aff><author-notes><corresp id="COR1">*Address correspondence to Ming Qiao, Microbiology and Infectious Diseases, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia. E-mail: <email>ming.qiao@health.sa.gov.au</email></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>10</month><year>2011</year></pub-date><volume>85</volume><issue>4</issue><fpage>724</fpage><lpage>731</lpage><history><date date-type="received"><day>03</day><month>8</month><year>2010</year></date><date date-type="accepted"><day>04</day><month>4</month><year>2011</year></date></history><permissions><copyright-statement>©The American Society of Tropical Medicine and Hygiene</copyright-statement><copyright-year>2011</copyright-year></permissions><abstract><p>A dengue vaccine effective against all four serotypes is urgently needed. However, safety and immunogenicity could be affected by prior exposure to flaviviruses. This open, controlled, phase IIa study was conducted in 35 healthy adults who had received monovalent, live attenuated Vero cell-derived dengue vaccine against dengue virus 1 (VDV1) or 2 (VDV2) or yellow fever (YF) vaccine 1 year before or who were flavivirus-naïve. All participants received one subcutaneous injection of tetravalent dengue vaccine (TDV) and were followed for 180 days. Previous vaccination did not increase reactogenicity, laboratory abnormalities, or incidence of vaccine viremia, but it did increase the neutralizing antibody response to dengue virus that persisted at day 180. There was no increase in YF antibodies in participants previously immunized with YF vaccine. Prior exposure to YF or monovalent dengue vaccines had no adverse effects on the safety or incidence of viremia associated with this TDV, but it increased immunogenicity.</p></abstract></article-meta><notes notes-type="disclaimer"><p>Disclaimers: Remi Forrat, Anh Wartel-Tram, and Jean Lang are employees of Sanofi Pasteur.</p></notes></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001574 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 001574 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:3183784
|texte= Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in Humans
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:21976579" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |